Cargando…
Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients
Colorectal Cancer (CRC) is one of the most common cancers accounting for 1.8 million new cases worldwide every year. Therefore, the identification of new potential therapeutic targets represents a continuous challenge to improve survival and quality of CRC patient’s life. We performed a microarray a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883247/ https://www.ncbi.nlm.nih.gov/pubmed/36707698 http://dx.doi.org/10.1038/s41598-023-28450-1 |
_version_ | 1784879467519279104 |
---|---|
author | Di Rosa, Michelino Di Cataldo, Antonio Broggi, Giuseppe Caltabiano, Rosario Tibullo, Daniele Castrogiovanni, Paola Imbesi, Rosa Lanteri, Raffaele Salomone, Federico Raciti, Giuseppina Li Volti, Giovanni |
author_facet | Di Rosa, Michelino Di Cataldo, Antonio Broggi, Giuseppe Caltabiano, Rosario Tibullo, Daniele Castrogiovanni, Paola Imbesi, Rosa Lanteri, Raffaele Salomone, Federico Raciti, Giuseppina Li Volti, Giovanni |
author_sort | Di Rosa, Michelino |
collection | PubMed |
description | Colorectal Cancer (CRC) is one of the most common cancers accounting for 1.8 million new cases worldwide every year. Therefore, the identification of new potential therapeutic targets represents a continuous challenge to improve survival and quality of CRC patient’s life. We performed a microarray analysis dataset consisting of colon biopsies of healthy subjects (HS) and CRC patients. These results were further confirmed in a clinical setting evaluating a series of CRC patients to assess the expression of Resistin-Like Beta (RETNLB) and to correlate it with their clinical data. Our results showed a significant reduction of RETNLB expression in CRC biopsies compared to the HS mucosa. Furthermore, such reduction was significantly associated with the TNM grade and patients’ age. Furthermore, a significantly positive correlation was found within mutated subjects for KRAS, TP53, and BRAF. In particular, patients with poor prognosis at 5 years exhibited RETNLB lower levels. In-silico analysis data were confirmed by histochemical analysis in a series of CRC patients recruited by our group. The results obtained provided that RETNLB low levels are associated with an unfavorable prognosis in CRC patients and its expression is also dependent on adjuvant therapy. Further studies are warranted in order to evaluate the molecular mechanisms underlying the role of RETNLB in CRC progression. |
format | Online Article Text |
id | pubmed-9883247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98832472023-01-29 Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients Di Rosa, Michelino Di Cataldo, Antonio Broggi, Giuseppe Caltabiano, Rosario Tibullo, Daniele Castrogiovanni, Paola Imbesi, Rosa Lanteri, Raffaele Salomone, Federico Raciti, Giuseppina Li Volti, Giovanni Sci Rep Article Colorectal Cancer (CRC) is one of the most common cancers accounting for 1.8 million new cases worldwide every year. Therefore, the identification of new potential therapeutic targets represents a continuous challenge to improve survival and quality of CRC patient’s life. We performed a microarray analysis dataset consisting of colon biopsies of healthy subjects (HS) and CRC patients. These results were further confirmed in a clinical setting evaluating a series of CRC patients to assess the expression of Resistin-Like Beta (RETNLB) and to correlate it with their clinical data. Our results showed a significant reduction of RETNLB expression in CRC biopsies compared to the HS mucosa. Furthermore, such reduction was significantly associated with the TNM grade and patients’ age. Furthermore, a significantly positive correlation was found within mutated subjects for KRAS, TP53, and BRAF. In particular, patients with poor prognosis at 5 years exhibited RETNLB lower levels. In-silico analysis data were confirmed by histochemical analysis in a series of CRC patients recruited by our group. The results obtained provided that RETNLB low levels are associated with an unfavorable prognosis in CRC patients and its expression is also dependent on adjuvant therapy. Further studies are warranted in order to evaluate the molecular mechanisms underlying the role of RETNLB in CRC progression. Nature Publishing Group UK 2023-01-27 /pmc/articles/PMC9883247/ /pubmed/36707698 http://dx.doi.org/10.1038/s41598-023-28450-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Di Rosa, Michelino Di Cataldo, Antonio Broggi, Giuseppe Caltabiano, Rosario Tibullo, Daniele Castrogiovanni, Paola Imbesi, Rosa Lanteri, Raffaele Salomone, Federico Raciti, Giuseppina Li Volti, Giovanni Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients |
title | Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients |
title_full | Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients |
title_fullStr | Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients |
title_full_unstemmed | Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients |
title_short | Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients |
title_sort | resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883247/ https://www.ncbi.nlm.nih.gov/pubmed/36707698 http://dx.doi.org/10.1038/s41598-023-28450-1 |
work_keys_str_mv | AT dirosamichelino resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT dicataldoantonio resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT broggigiuseppe resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT caltabianorosario resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT tibullodaniele resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT castrogiovannipaola resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT imbesirosa resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT lanteriraffaele resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT salomonefederico resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT racitigiuseppina resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients AT livoltigiovanni resistinlikebetareductionisassociatedtolowsurvivalrateandisdownregulatedbyadjuvanttherapyincolorectalcancerpatients |